1.20
price down icon2.44%   -0.03
pre-market  Vorhandelsmarkt:  1.22   0.02   +1.67%
loading
Schlusskurs vom Vortag:
$1.23
Offen:
$1.23
24-Stunden-Volumen:
3.91M
Relative Volume:
0.81
Marktkapitalisierung:
$435.81M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.50
EPS:
-0.8
Netto-Cashflow:
$-162.37M
1W Leistung:
+4.35%
1M Leistung:
+60.00%
6M Leistung:
+42.86%
1J Leistung:
-43.13%
1-Tages-Spanne:
Value
$1.155
$1.24
1-Wochen-Bereich:
Value
$1.135
$1.43
52-Wochen-Spanne:
Value
$0.2836
$2.45

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name
Firmenname
Lexicon Pharmaceuticals Inc
Name
Telefon
(281) 863-3000
Name
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Name
Mitarbeiter
103
Name
Twitter
@LexPharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
LXRX's Discussions on Twitter

Vergleichen Sie LXRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LXRX
Lexicon Pharmaceuticals Inc
1.20 417.65M 1.21M -177.12M -162.37M -0.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-05 Herabstufung Leerink Partners Outperform → Market Perform
2024-06-17 Eingeleitet H.C. Wainwright Buy
2024-04-30 Eingeleitet Leerink Partners Outperform
2023-03-07 Eingeleitet Jefferies Hold
2022-08-12 Eingeleitet Piper Sandler Overweight
2021-01-29 Hochstufung JP Morgan Underweight → Neutral
2021-01-29 Herabstufung Wedbush Outperform → Neutral
2020-12-08 Hochstufung Citigroup Neutral → Buy
2020-11-18 Hochstufung Gabelli & Co Hold → Buy
2019-12-11 Herabstufung Gabelli & Co Buy → Hold
2019-11-08 Herabstufung Citigroup Buy → Neutral
2019-09-11 Hochstufung Gabelli & Co Hold → Buy
2019-07-29 Herabstufung Stifel Buy → Hold
2019-03-25 Hochstufung Gabelli & Co Sell → Hold
2018-07-31 Bestätigt Stifel Buy
2018-02-23 Herabstufung Needham Buy → Hold
2018-02-14 Herabstufung JP Morgan Neutral → Underweight
2017-03-01 Bestätigt H.C. Wainwright Buy
2017-03-01 Bestätigt Wedbush Outperform
2016-10-07 Eingeleitet H.C. Wainwright Buy
2016-08-05 Bestätigt Wedbush Outperform
2016-08-02 Eingeleitet Citigroup Buy
2016-03-02 Bestätigt Wedbush Outperform
2015-11-09 Bestätigt Wedbush Outperform
2015-09-28 Hochstufung Gabelli & Co Sell → Hold
2015-09-18 Herabstufung Gabelli & Co Hold → Sell
2015-08-10 Herabstufung JP Morgan Overweight → Neutral
Alle ansehen

Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten

pulisher
Jul 22, 2025

What drives Lexicon Pharmaceuticals Inc. stock pricePowerful market insights - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Lexicon Pharmaceuticals Inc. a good long term investmentUnstoppable profit momentum - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Lexicon Pharmaceuticals Inc. Stock Analysis and ForecastOver 200% growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Lexicon Pharmaceuticals Inc. stockTremendous gains - Autocar Professional

Jul 22, 2025
pulisher
Jul 20, 2025

H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

Lexicon Pharmaceuticals: A High-Potential Biotech Play in the Diabetes Space - AInvest

Jul 20, 2025
pulisher
Jul 18, 2025

10 Hot Penny Stocks to Invest in Now - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) - The Manila Times

Jul 18, 2025
pulisher
Jul 18, 2025

Lexicon Pharmaceuticals to Present Study on Diabetic Peripheral Neuropathic Pain at ASPN 2025 Conference - Quiver Quantitative

Jul 18, 2025
pulisher
Jul 16, 2025

What makes Lexicon Pharmaceuticals Inc. stock price move sharplyTop ROI Selections - beatles.ru

Jul 16, 2025
pulisher
Jul 11, 2025

Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap touched US$389m last week, benefiting both private equity firms who own 48% as well as institutions - simplywall.st

Jul 11, 2025
pulisher
Jul 09, 2025

Lexicon Pharmaceuticals (LXRX) Soars 16.74% on Technical Signals - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Lexicon Pharmaceuticals Defies Expectations: What Lies Ahead? - StocksToTrade

Jul 09, 2025
pulisher
Jul 04, 2025

Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension - The Globe and Mail

Jul 04, 2025
pulisher
Jul 03, 2025

Lexicon Pharmaceuticals receives additional compliance period from Nasdaq - Investing.com

Jul 03, 2025
pulisher
Jul 02, 2025

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm - ACCESS Newswire

Jul 02, 2025
pulisher
Jun 30, 2025

While institutions own 28% of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), private equity firms are its largest shareholders with 48% ownership - Yahoo Finance

Jun 30, 2025
pulisher
Jun 27, 2025

HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat

Jun 27, 2025
pulisher
Jun 26, 2025

Congestive Heart Failure Market to Expand Significantly by 2034, States DelveInsight Report | Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, Merck Sharp & Dohme LLC, Corthera - Barchart.com

Jun 26, 2025
pulisher
Jun 24, 2025

Lexicon Pharmaceuticals (LXRX) Receives Buy Rating from HC Wainwright & Co. | LXRX Stock News - GuruFocus

Jun 24, 2025
pulisher
Jun 24, 2025

H.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stock By Investing.com - Investing.com Canada

Jun 24, 2025
pulisher
Jun 23, 2025

Breakthrough: Sotagliflozin Cuts Dangerous Low Blood Sugar Events in Type 1 Diabetes Patients - Stock Titan

Jun 23, 2025
pulisher
Jun 18, 2025

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) | LXRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - TradingView

Jun 18, 2025
pulisher
Jun 18, 2025

New Clinical Data Shows Lexicon's Diabetes Drug Effective Across All Kidney Function LevelsADA Conference - Stock Titan

Jun 18, 2025
pulisher
Jun 13, 2025

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31% - simplywall.st

Jun 13, 2025
pulisher
Jun 11, 2025

Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple - MarketScreener

Jun 11, 2025
pulisher
Jun 08, 2025

Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com

Jun 08, 2025
pulisher
Jun 05, 2025

Lexicon Pharmaceuticals at Jefferies Conference: Strategic Partnerships and Pipeline Progress - Investing.com Canada

Jun 05, 2025
pulisher
Jun 03, 2025

Earnings call transcript: Lexicon Pharmaceuticals Q4 2024 beats EPS forecast By Investing.com - Investing.com UK

Jun 03, 2025
pulisher
May 30, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by Northern Trust Corp - Defense World

May 30, 2025
pulisher
May 29, 2025

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times

May 29, 2025
pulisher
May 21, 2025

Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential - MSN

May 21, 2025
pulisher
May 20, 2025

Lexicon Pharmaceuticals' Q1 2025: Unpacking Contradictions in Trial Designs, FDA Strategies, and Partnership Plans - AInvest

May 20, 2025
pulisher
May 19, 2025

Lexicon (LXRX) Advances Study on Sotagliflozin for Heart Conditions | LXRX Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

LXRXLexicon Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan

May 19, 2025
pulisher
May 19, 2025

Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts - simplywall.st

May 19, 2025
pulisher
May 17, 2025

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st

May 17, 2025
pulisher
May 17, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance

May 17, 2025
pulisher
May 15, 2025

Lexicon targets late 2025 Phase 3 start for pilavapadin and expands LX9851 partnership with Novo Nordisk - MSN

May 15, 2025
pulisher
May 15, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025
pulisher
May 14, 2025

Lexicon Pharmaceuticals (LXRX) Reports Higher Q1 Revenue and Key Strategic Developments | LXRX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Lexicon Pharmaceuticals (LXRX) Pre-Earnings Options Activity Rev - GuruFocus

May 14, 2025

Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):